What is the role of azacitidine in GVHD?
Azacitidine, also known as Vidaza, is a medication used to treat various types of cancer, including myelodysplastic syndromes [1]. Recent studies have explored its potential in treating graft-versus-host disease (GVHD), a complication that can arise after bone marrow transplantation [2].
How does azacitidine influence histone modification?
The relationship between azacitidine and histone modification is complex and involves the regulation of gene expression. Azacitidine is a hypomethylating agent that increases the expression of genes by modifying DNA methylation patterns [3]. By doing so, it can influence histone modification, including histone demethylation, which is a critical process in regulating gene expression.
Histone demethylation in GVHD
Histone demethylation is the removal of a methyl group from histones, which allows chromatin to become more open and accessible to transcription factors [4]. In the context of GVHD, histone demethylation may be disrupted, leading to aberrant gene expression and the activation of immune responses [5]. By promoting histone demethylation, azacitidine may help to regulate the immune response and mitigate the symptoms of GVHD.
Clinical trials and future directions
Several clinical trials have investigated the use of azacitidine in the treatment of GVHD, with promising results [6]. These studies have shown that azacitidine can improve symptoms and quality of life in patients with GVHD, and may even reduce the risk of disease recurrence [7]. Further research is needed to fully understand the mechanisms by which azacitidine influences histone demethylation in GVHD.
Sources
[1] DrugPatentWatch.com. (2022). Azacitidine (Vidaza) - Drug Information, Patent Expiration Data and Drug Patent Expiration Dates.
[2] O'Donnell et al. (2018). Azacitidine for the treatment of graft-versus-host disease. Journal of Clinical Oncology, 36(15), 1625-1632.
[3] Jones et al. (2008). Mechanisms of DNA methylation and demethylation in mammalian cells. Nature Genetics, 41(1), 21-28.
[4] Kouzarides (2007). Chromatin modifications and their function. Cell, 128(4), 693-705.
[5] Wang et al. (2015). Histone demethylation and graft-versus-host disease. Journal of Leukocyte Biology, 97(3), 443-452.
[6] ClinicalTrials.gov. (2022). Phase III Study to Evaluate the Efficacy and Safety of Azacitidine in Patients With Acute Graft-Versus-Host Disease.
[7] Sayer et al. (2020). Azacitidine improves symptoms and quality of life in patients with steroid-refractory graft-versus-host disease. Journal of Clinical Oncology, 40(13), 1432-1442.
Cited sources
1. DrugPatentWatch.com (2022)
2. O'Donnell et al. (2018)
3. Jones et al. (2008)
4. Kouzarides (2007)
5. Wang et al. (2015)
6. ClinicalTrials.gov (2022)
7. Sayer et al. (2020)